Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings
Posted inGastroenterology news Pathology & Lab Medicine

Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings

An epigenome-wide study (EPIC‑CD) identified peripheral blood DNA methylation panels that predicted response to vedolizumab and ustekinumab (validated AUC 0.75 each) but failed to predict adalimumab response. Models worked best in biologic‑naïve patients and outperformed available clinical decision support tools.
Evaluating Self-Collected Urine and Vaginal Samples for HPV Genotyping in Cervical Cancer Screening Among Japanese Women
Posted inInfectious Diseases news Pathology & Lab Medicine

Evaluating Self-Collected Urine and Vaginal Samples for HPV Genotyping in Cervical Cancer Screening Among Japanese Women

This study assesses the feasibility and performance of using self-collected urine and vaginal samples with the BD Onclarity® HPV assay for cervical cancer screening in Japanese women with abnormal cytology, highlighting concordance and sensitivity metrics compared to clinician-collected cervical samples.
Impact of Epstein-Barr Virus Serology on Oral HPV Infection Dynamics in Early Childhood: Insights from the Finnish Family HPV Cohort
Posted inDentistry Infectious Diseases news Pathology & Lab Medicine Pediatrics

Impact of Epstein-Barr Virus Serology on Oral HPV Infection Dynamics in Early Childhood: Insights from the Finnish Family HPV Cohort

This study explores how early Epstein-Barr virus (EBV) infection and immune responses influence oral human papillomavirus (HPV) infections in children, revealing the interplay between EBV serology, paternal education, and oral HPV acquisition and clearance during the first three years of life.
Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes as a Biomarker in Anti-PD-1-Based Therapy for Advanced Melanoma: Clinical Evidence and Translational Perspectives
Posted inAI Oncology Pathology & Lab Medicine Specialties

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes as a Biomarker in Anti-PD-1-Based Therapy for Advanced Melanoma: Clinical Evidence and Translational Perspectives

AI-detected tumor-infiltrating lymphocytes on routine histology independently predict response and survival in advanced melanoma treated with anti-PD-1 therapies, outperforming manual scoring and offering an accessible biomarker for immune checkpoint inhibitor outcomes.
Standardizing Pathological Response Reporting After Neoadjuvant Therapy in Kidney Cancer: New International Guidelines
Posted inOncology Pathology & Lab Medicine Specialties

Standardizing Pathological Response Reporting After Neoadjuvant Therapy in Kidney Cancer: New International Guidelines

International experts issue consensus guidelines for sampling and reporting pathological response to neoadjuvant therapy in renal cell carcinoma, recommending standardized specimen sampling and quantification of residual viable tumor to enable reliable trial endpoints and future clinical use.
Clinical Decision Tool Integrating Decision Tree, Point-of-Care CRP Testing, and Safety Netting to Optimize Antibiotic Use in Acutely Ill Children: Evidence from the ARON Pragmatic Trial and Contextual Literature
Posted inClinical Updates Critical Care news Pathology & Lab Medicine Pediatrics Public Health Specialties

Clinical Decision Tool Integrating Decision Tree, Point-of-Care CRP Testing, and Safety Netting to Optimize Antibiotic Use in Acutely Ill Children: Evidence from the ARON Pragmatic Trial and Contextual Literature

The ARON trial demonstrated that a clinical decision tool combining decision tree, point-of-care CRP testing, and safety-netting advice safely reduces antibiotic prescribing in acutely ill children without delaying recovery or increasing healthcare utilization.
Early ctDNA Dynamics Predict Long-Term Survival in dMMR/MSI-H Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
Posted inOncology Pathology & Lab Medicine Specialties

Early ctDNA Dynamics Predict Long-Term Survival in dMMR/MSI-H Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors

Change in circulating tumor DNA (ctDNA) one month after treatment initiation predicts progression-free and overall survival in patients with dMMR/MSI-H metastatic colorectal cancer receiving immune checkpoint inhibitors, offering a potential biomarker for therapeutic decision-making.